TY - JOUR
T1 - Activity of novobiocin against methicillin-resistantstaphylococcusaureus
AU - Walsh, Thomas J.
AU - Hansen, Sharon L.
AU - Tatem, Beverly A.
AU - Auger, Francois
AU - Standiford, Harold C.
N1 - Funding Information:
This study was supported by the Veterans Administration and by a grant from The Upjohn Company, Kalamazoo, Michigan.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 1985/4
Y1 - 1985/4
N2 - As infections due to methicillin-resistantStaphylococcus aureus become increasingly prevalent, newer alternative antibiotics, especially those which are orally administered, will be required. In order to provide anm-vitro basis for selecting alternative antibiotics, we studied the susceptibility of 103 strains of methicillin-resistantStaph aureus from seven institutions to oral antimicrobial agents. Novobiocin, nfampicin, and tnmethoprim-sulphamethoxazole had excellentin-vitro activity against virtually all strains of methicillin-resistantStaph aureus. The MIC90 and MBC90 of novobiocin against methicillin-resistantStaph aureus were 0-25 mg/1. Since previously reported achievable serum levels with oral novobiocin are 100 to 200 times its MIC90 against methicillin-resistant Staph. aureus, novobiocin should be evaluated further for combination therapy with nfampicin or trimethopnm-sulphamethoxazole.
AB - As infections due to methicillin-resistantStaphylococcus aureus become increasingly prevalent, newer alternative antibiotics, especially those which are orally administered, will be required. In order to provide anm-vitro basis for selecting alternative antibiotics, we studied the susceptibility of 103 strains of methicillin-resistantStaph aureus from seven institutions to oral antimicrobial agents. Novobiocin, nfampicin, and tnmethoprim-sulphamethoxazole had excellentin-vitro activity against virtually all strains of methicillin-resistantStaph aureus. The MIC90 and MBC90 of novobiocin against methicillin-resistantStaph aureus were 0-25 mg/1. Since previously reported achievable serum levels with oral novobiocin are 100 to 200 times its MIC90 against methicillin-resistant Staph. aureus, novobiocin should be evaluated further for combination therapy with nfampicin or trimethopnm-sulphamethoxazole.
UR - http://www.scopus.com/inward/record.url?scp=0021960420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021960420&partnerID=8YFLogxK
U2 - 10.1093/jac/15.4.435
DO - 10.1093/jac/15.4.435
M3 - Article
C2 - 3847438
AN - SCOPUS:0021960420
SN - 0305-7453
VL - 15
SP - 435
EP - 440
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 4
ER -